Home / Health / Wuxi Cancer Drug Approved in US After Patient's Transpacific Quest
Wuxi Cancer Drug Approved in US After Patient's Transpacific Quest
5 Nov
Summary
- A US patient's desperate search for a Chinese cancer drug led to its US approval.
- Sunvozertinib, a Dizal Pharma drug, is the first China-developed drug approved in the US.
- The drug's US launch on Oct 23, 2026, marks a major milestone for Wuxi's industry.
A cancer drug developed in Wuxi, China, has achieved a significant milestone with its recent approval and launch in the United States. Sunvozertinib, created by Dizal Pharma, is the first Chinese-developed, first-in-class drug to receive US approval. This momentous event, announced on October 23, 2026, underscores the growing global impact of pharmaceutical innovation emerging from Wuxi.
The drug's journey to US approval gained particular attention through the story of Debbie Doppelt, a US patient battling advanced lung cancer. In January 2025, when conventional treatments were insufficient, her son Max traveled to Shanghai to obtain sunvozertinib, as it was not yet commercially available in the US.
This successful acquisition and subsequent positive response to the medication paved the way for broader recognition. Dizal Pharma's announcement of sunvozertinib's official launch in the US on October 23, 2026, represents a landmark achievement for both the company and the Chinese pharmaceutical industry at large.
